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Abstract: The migration, survival and proliferation of cells is the basis for all physiologic and pathologic pro-
cesses in the human body. All these reactions are regulated by a complex chemokine network that guides lym-
phocytes homing, chemotaxis, adhesion and interplay between immunologic system response cells. Chemokines
are also responsible for metastatic dissemination of cancers, including Hodgkin’s and non-Hodgkin’s lympho-
mas. The purpose of this study was to determine chemokine gene expression (CXCL8, CXCL10, CCL2, CCL3,
CCL4 and CCL5) in lymphoma lymph nodes compared to their expression in reactive lymph nodes. We also
analyzed the influence of chemokine gene expression on the survival of lymphoma patients. Chemokine gene
expression was evaluated in 37 lymphoma lymph nodes and in 25 samples of reactive lymph nodes. Gene expres-
sion of chemokines CXCL8, CXCL10, CCL2, CCL3, CCL4 and CCL5 was measured using the PCR method.
Statistical analysis was performed using CSS Statistica for Windows (version 7.0) software. Probability values <
< 0.05 were considered statistically significant and those between 0.05 and 0.1 as indicative of a trend. We found
lower CXCL8 and CXCL10 gene expression in lymphoma lymph nodes compared to reactive lymph nodes. In
the cases of CCL2 and CCL3, expression in lymphomas was higher than in reactive lymph nodes. Patients with
high expression of CCL2 and CXCL10 had shorter survival. (Folia Histochemica et Cytobiologica 2011; Vol. 49,
No. 2, pp. 240–247)
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Introduction
Chemokines are small proteins with low molecular
mass, which display a pleiotropic action and are se-
creted mainly by leukocytes and some other tissue
cells. The chemokine family is divided into four sub-
groups, based on conservative cysteine residues in
polypeptide chain. Chemokines act through specific
transmembrane G-protein-coupled receptors [1].
Chemokines play an important role in the homeo-
static process, particularly in regulating the migration
and homing of leukocytes in peripheral lymphatic
organs [2, 3]. On the other hand, it is known that
chemokines take part in many pathological process-
es, such as inflammation, the neoplastic process, and
cancer progression and dissemination [4, 5].
Non-Hodgkin’s lymphoma (nHL) comprises
a heterogenous group of lymphatic system neoplastic
disorders. Lymphomas derive from lymphocytes B,
T or NK or their precursors. It has been suggested
that chemokines, as factors regulating immunocom-
petent cells migration and activity, are responsible for
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the disruption of immunologic processes and could
have an important role in lymphomagenesis. Lympho-
mas can localize not only to lymph nodes, but dis-
seminate into different extranodal organs. Chemok-
ines also play an important role in the migration of
lymphoma cells [6].
Hodgkin’s lymphoma (HL) is a particular type of
cancer in which the tumor mass contains reactive cells
(such as lymphocytes, plasmocytes, eosinophils, his-
tiocytes, fibroblasts) and a clonal population of
B-cells unable to secrete immunoglobulins (RSC, Reed-
-Sternberg cells) [7]. RSC comprise about 1% of all
tumor cells. It has been suggested that infiltration of
a tumor by reactive cells is caused by RSC chemok-
ine secretion and their chemotactic activity on reac-
tive cells. Higher expression of chemokines CXCL9,
CXCL10, CCL5, and CCL3 has been demonstrated in
tissues infiltrated by HL [8], but expression of each of
these chemokines has been linked to a different cell
population [9]. The previous theory suggested the dom-
ination of Th2 immunologic response in HL [10]. The
latest studies have shown a predomination of regula-
tory T cells rather than Th2 lymphocytes [11] and ex-
plained why neoplastic cells can in this case avoid anti-
neoplastic immunologic control.
NHL and HL are two different groups of diseases
in both a histopathological and a clinical sense. The
involvement of lymph nodes occurs in practically all
cases, but nHL has a stronger predisposition for ex-
tranodal localization than HL. As a process that al-
ways accompanies cancer, inflammation joins both
types of lymphoma. Tumor cells secrete chemokines
and cytokines, attracting inflammation cells, which
also can promote tumor growth and progression [12].
On the other hand, lymphadenopathy can be present
in both lymphoma and inflammation. Lymph node
metastases and clinical reactive lymph node enlarge-
ment differs in the profile of chemokines and their
receptors expressed [13].
The purpose of this study was to evaluate proin-
flammatory chemokine gene expression (CXCL8,
CXCL10, CCL2, CCL3, CCL4 and CCL5) in lympho-
ma lymph nodes compared to their expression in re-
active lymph nodes. We also analyzed the influence
of chemokine gene expression on the survival of lym-
phoma patients.
Material and methods
Lymph nodes. Chemokine gene expression was evaluated
in 37 lymphoma lymph nodes taken from patients (16 wom-
en, 21 men, aged 18–81 years; median age 43) at the time of
diagnosis. It was also evaluated in 25 samples of reactive
lymph nodes (taken from 15 women and 10 men aged 18–
–59; median age 32) (Table 1).
Methods. Samples of the studied lymphomas (37) and re-
active lymph node tissues (25) were divided into two parts.
One was fixed in 10% buffered formalin and then embed-
ded in paraffin. Sections were stained with hematoxylin and
eosin and evaluated histopathologically. The second parts
of the lymph nodes, used for gene expression analysis, were
snap frozen in liquid nitrogen and stored at –70°C.
Chemokine gene expression analysis. Total RNA was ex-
tracted from the frozen tissue samples using Trizol reagent
(Invitrogen Corp., Carlsbad, CA, USA). The amount of iso-
lated total RNA was estimated quantitatively by spectro-
photometric measurement and qualitatively by electro-
phoretical view. First-strand cDNA was synthesized using
First-Strand Synthesis System (Stratagene, La Jolla, CA,
USA) according to the manufacturer’s specifications. cDNA
used for PCR was standardized toward to b-actin mRNA.
Briefly, b-actin was initially amplified and quantified with
serial dilutions of cDNA from each sample. CXCL8,
CXCL10, CCL2, CCL3, CCL4 and CCL5 were then ampli-
fied in each sample containing identical amounts of b-actin
mRNA. Gene expression was estimated in arbitrary units
(AU) using a 0 to 3 point AU scale. PCR was conducted
using primer pairs for CCL2 (sense TCC AGC ATG AAA
GTC TCT GC, antisense TGG AAT CCT GAA CCC ACT
TC, 245 bp); CCL3 (sense GTC ATC TTC CTA ACC AAG
CG, antisense TGT GGC TGT TTG GCA ACA AC, 229
bp); CCL4 (sense AGG AAG CTT CCT CGC AAC TT,
antisense AGT CCT GAG TAT GGA GGA GA, 244 bp);
CCL5 (sense CAT TGC TAC TGC CCT CTG CG, anti-
sense GGG TTG GCA CAC ACT GTT CG, 192 bp);
CXCL8 (sense TTG GCA GCC TTC CTG ATT, antisense
Table 1. Patient characteristics
Lymphoma No. of Sex Median age
type patients  F/M (range) years
B-cell lymphoma 26 12/14 57 (26–73)
FL 7   
MCL 4  
SLL 4
DLBCL 4
MZL 3
BL 2
MM 1
HCL 1   
T-cell lymphoma 4 0/4 59 (41–81)
PTCL 1   
ALCL 3   
Hodgkin’s 7 4/3 27 (21–58)
lymphoma
FL — follicular lymphoma; MCL — mantle cell lymphoma;
SLL — small lymphocytic lymphoma; DLBCL — diffuse large B-cell
lymphoma; MZL — marginal zone lymphoma; BL — Burkitt lymphoma;
MM — multiple myeloma; HCL — hairy cell leukemia; PTCL — peripheral
T-cell lymphoma; ALCL — anaplastic large cell lymphoma
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AAC TTC TCC ACA ACC CTC TG, 403 bp); CXLC10
(sense TGG CAT TCA AGG AGT ACC TC, antisense TGT
AGG GAA GTG ATG GGA GA, 326 bp); and b-actin
(sense GGG TCA GAA GGA TTC CTA TG, antisense
GGT CTC AAA CAT GAT CTG GG, 250 bp).
Amplification was performed in a MJ Research PTC-
-200 Peltier thermal cycler DNA engine (MJ Research Inc,
Watertown, MA, USA). The PCR conditions were 35 cy-
cles at 95°C for 30 seconds, 55°C (for b-actin, CXCL10), or
60°C (for CCL2-5), or 68°C (for CXCL8) for 30 seconds,
and 72°C for 30 seconds, followed by final extension at 72°C
for ten minutes.
The size of PCR products was determined by agarose
gel electrophoresis.
Statistical analyses. Univariate analyses were performed
using Fisher’s exact test or c2 test. Cumulative survival was
analyzed via Kaplan–Meier plots. Probability values < 0.05
were considered statistically significant and those between
0.05 and 0.1 as indicative of a trend. Statistical analysis was
performed using Statistica for Windows (version 7.0) soft-
ware (Sta-Soft Inc., Tulsa, OK, USA).
Results
CXCL8 gene expression
In most cases, CXCL8 gene expression was low, or
was not detected at all. In four samples: two HL, one
T-cell lymphoma and one reactive node, CXCL8 ex-
pression was increased (2 or 3 AU). In 62% of cases
of B-cell lymphoma, CXCL8 expression was not
shown. Only FL (five cases) and SLL (four cases) re-
vealed gene expression at the level of 1 AU. In 50%
of reactive lymph nodes, CXCL8 expression was at
1 AU level. In other reactive lymph nodes, expression
was not detected. In three T-cell lymphomas, there
was low (1 AU) expression of the CXCL8 gene. In
one case, expression was detected at a 3 AU level.
CXCL10 gene expression
CXCL10 expression was studied in 62 lymph nodes.
In reactive lymph nodes, expression was high in 18/
25 (72%) cases. All lymphoma lymph nodes expressed
CXCL10 at a lower (1 AU) level (p = 0.002). In all
T-cell lymphomas, expression at a level of 2 AU was
observed. In five cases of HL, expression of chemok-
ine was at a low (1 AU) level. Two other cases did not
express CXCL10. In B-cell lymphomas, the level of
CXCL10 expression was statistically lower than in
reactive lymph nodes (p = 0.002). In these patients,
a higher expression (2 AU) was detected in DLBCL,
BL and MCL. In lymphoma patients, we found a cor-
relation between overall survival and CXCL10 expres-
sion. Patients with higher CXCL10 expression had
statistically shorter survival than those with low
CXCL10 expression (p = 0.002) (Figure 1).
CCL2 gene expression
Analysis of lymphoma lymph nodes revealed a statis-
tically higher level of CCL2 expression compared to
reactive lymph nodes (p = 0.0008). In 19/26 (73%) of
B-cell lymphomas, and all T-cell lymphomas, a 2–3
AU expression was observed. In 4/7 (57%) cases of
HL, expression of CCL2 was detected. Expression of
CCL2 was present in 7/25 (28%) of reactive lymph
nodes, but was statistically lower than in B-cell lym-
phomas (p = 0.001). Particularly high CCL2 expres-
sion was characteristic for DLBCL and Burkitt lym-
phoma. In FL, MCL and SLL, expression was com-
parable at around 1–2 AU. In multiple myeloma and
hairy cell leukemia, the expression of CCL2 was not
detected. In lymphoma patients, we found a correla-
tion between overall survival and CCL2 expression.
Patients with higher CCL2 expression had statistical-
ly shorter survival than those with low CCL2 expres-
sion (p = 0.004).
CCL3 gene expression
Almost all (33/37; 89%) lymphoma lymph nodes
showed a CCL3 expression of 2 AU. In reactive lymph
nodes, expression was more differentiated (0 to 3 AU).
Analysis of the total group of lymphoma lymph nodes
revealed statistically higher CCL3 gene expression
(≥ 2 AU) than in reactive lymph nodes (9/25; 36%),
p = 0.01. Low expression was observed in only four lym-
phoma lymph nodes: one HL, two FL and one MZL.
Figure 1. Kaplan–Meier cumulative survival plots compa-
ring lymphoma patients with different CXCL10 expressions:
Group 1: 2–3 AU CXCL10 expression; Group 2: 1 AU
CXCL10 expression; Group 3: 0 AU CXCL10 expression
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CCL4 gene expression
Expression of CCL4 was detected in 58/62 (94%)
analyzed lymph nodes. In most cases expression was
at a high (≥ 2 AU) level. There was no statistically
significant difference between lymphoma and reac-
tive lymph nodes.
CCL5 gene expression
CCL5 gene expression was observed in 60/62 (97%)
lymph nodes (no expression in one MM and one re-
active lymph node). All lymphoma types revealed
higher, but comparable, CCL5 expression level (in
30% of cases, expression equaled 3 AU). In almost
all (except one) HL lymph nodes, expression was
equal to 2 AU. In T-cell lymphomas, expression var-
ied between 1 and 3 AU. In B-cell lymphoma, a par-
ticularly high expression was found in BL and 50%
of MCL (Figures 2 and 3).
Discussion
Chemokines are small proteins (812 kD) which bind
to specific receptors on target cells, and can influence
proliferation, migration, apoptosis and activation of
normal and neoplastic cells [14–17]. Research is re-
vealing their role in inflammation, immunologic re-
actions, organ formation and organization, and car-
cinogenesis [18].
In our study we analyzed proinflammatory
chemokine gene expression in lymphomas (HL and
nHL) and reactive lymph nodes. The state of inflam-
mation very often accompanies neoplasms and seems
to be a promoting factor for cancer development.
Neoplastic cells can secrete chemokines, which in an
autocrine manner stimulate their growth (for exam-
ple: in melanoma CXCL1, CXCL2, CXCL3, CXCL4
[19]), simultaneously causing recruitment of inflam-
matory cells. A special connection between inflam-
mation and cancer can be observed in HL, in which
infiltrating reactive cells secrete an increased amount
of chemokines (mainly of the CC group) [9]. Neo-
plastic and reactive lymphadenopathy can be differ-
entiated by histopathologic examination of the lymph
node. The migration capacity of cells towards lymph
nodes depends on chemokines and receptors expres-
sion, but, importantly, one receptor can bind chemok-
ines of different affinities. Corcione et al. showed
migration of MCL cells in vitro in response to CCL19
and CXCL12 [19].
CXCL8 can be produced by leukocytes (mono-
cytes, T lymphocytes, neutrophils, NK cells) and also
fibroblasts and epithelial cells. Its expression can be
induced by proinflammatory cytokines (interleukin 1)
and tumor necrosis factor-a (TNFa). CXCL8 is re-
sponsible mainly for leukocyte migration to periph-
eral tissues, and also for degranulation of neutro-
phils. In our study we showed low expression of
CXCL8. In both B-cell lymphomas and reactive
lymph nodes, expression was almost undetectable.
CXCL8 shows an activity for freshly-isolated T lym-
phocytes, but incubation of lymphocytes causes
a progressive drop of receptors binding CXCL8 on
T lymphocytes and is combined with decreased im-
munologic response [20]. CXCL8 indirectly can in-
duce T lymphocytes chemotaxis through release of
chemoattractants from neutrophils and is also
chemotactic for B cells [21]. Fujii et al. studied the
expression of chemokines in DLBCL with different
localizations (nodal, extranodal, central nervous sys-
tem involvement) [22]. In general, expression was
low, but higher in patients with nodal localization.
Another study revealed CXCL8 expression in HL-
-stimulated lines and in the serum of patients with
HL [23]. Research in situ did not show either the
presence of CXCL8 transcript nor protein in RSC,
but CXCL8 was present in reactive neutrophils in
HL [24]. Those results are in line with ours. It is
known that neutrophils play an important role in
neoplastic infiltration, because they attract inflam-
mation cells and sustain the inflammation process.
CXCL10 chemokine is a key mediator of response
to interferon. CXCL10 attracts to the site of inflam-
mation Th1 activated lymphocytes, and also can in-
hibit angiogenesis [25]. CXCL10 expression occurs
in activated mononuclear cells, keratinocytes, fibro-
blasts, endothelial cells and T lymphocytes. In vitro
CXCL10 inhibits colony formation by human hemato-
poietic cells in bone marrow [26] and shows strong
anti-neoplastic activity in vivo [27]. CXCL10 is chemo-
tactic for monocytes and T lymphocytes and can pro-
mote T cell adhesion to the endothelium [28].
We found high CXCL10 expression level in 72%
of studied lymph nodes. All lymphoma lymph nodes
had significantly lower CXCL10 expression. Maggio
et al., using the RT-PCR method, demonstrated
CXCL10 expression in HL cell lines, but not in NHL
cell lines [29]. CXCL10 is a marker of immunologic
reactions and its expression is stimulated by proin-
flammatory factors. Before CXCL10 was found to be
a chemotactic substation, it had been used to deter-
mine interferon-gamma (INFg) levels. Our results
might suggest a decreased grade of polarization to-
wards Th2 population in the inflammation process.
More probably, it is a process with general proinflam-
matory stimulation, with both Th1 and Th2 lympho-
cyte recruitment.
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We also noticed an important correlation between
CXCL10 expression and patient survival: increased
expression was connected to shorter survival. Grade
of CXCL10 expression as marker protein of INFg
reflects potential Th1 response. Teichmann et al.,
analyzing CXCL10 expression in HL, came to a sim-
ilar conclusion [30]. INFg alone can be a strong anti-
-cancer factor. Additionally activated by INFg cyto-
toxic lymphocytes and NK cells could play a role in
anti-neoplastic control. Thus it is surprising that
a negative correlation between CXCL10 expression
and clinical prognosis was found in our study.
CXCL10 alone has angiostatic and apoptotic activi-
ty, and should limit cancer progression.
CCL2 induces chemotaxis of monocytes lympho-
cytes T and NK, dendritic cells and basophils. CCL2
can be secreted not only by tumor cells but also by
stromal cells such as fibroblasts, endothelial cells and
monocytes. CCL2 inhibits tumor growth through ac-
tivity of T lymphocytes. But on the other hand, it pro-
motes cancer progression (tumor-associated mac-
rophages recruitment and proangiogenic activity).
Recently, we demonstrated increased mean CCL2
plasma levels in untreated patients with acute mye-
loid leukemia [31]. The role of CCL2 in nHL is yet to
be established. Lucciani et al. showed CCL2 expres-
sion in 23/24 HL, 7/17 B-cell nHL and 13/25 cancers
deriving from lungs, breast, thyroid and ovary [23].
Figure 2. Chemokine gene expressions in different types of lymphomas and reactive lymph nodes
Figure 3. Comparison of proportional gene expression in subgroups of B- and T-cell lymphomas, Hodgkin’s lymphoma
and reactive lymph nodes. Gray — the number of lymph nodes with low expression (0, 1 AU); black — the number of
lymph nodes with high expression (2, 3 AU). ‘p’ values represent comparison between special lymphoma subgroup and
reactive lymph nodes
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An increased level of CCL2 could be linked to a higher
proinflammatory cytokine expression. For example,
interleukin-6 and TNFa are responsible for “B” symp-
toms occurrence. Husson et al. noticed that in follicu-
lar lymphoma, an increase in CCL2 secretion is sec-
ondary to higher TNFa production, and that chemot-
axis of neoplastic cells can be modulated by CCL2 [32].
In our study, CCL2 expression in lymphoma lymph
nodes was significantly higher than in reactive lymph
nodes. This is probably linked to increased angiogen-
esis in the lymphoproliferative process. Monitoring
of chemokines with proangiogenic activity could have
prognostic value. Our present study found high CCL2
expression to result in shorter survival, which can have
a prognostic impact in nHL. This finding can have
therapeutic implication with use of angiogenesis in-
hibitors in clinical practice.
CCL3 is a chemokine with an important role in
multiple myeloma [33, 34]. CCL3 stimulates differ-
entiation, increases osteolytic activity and attracts
osteoclasts. There has been shown to be a correla-
tion between increased CCL3 level and grade of os-
teolytic features and stage of diseases in multiple
myeloma patients [34, 35]. We observed higher CCL3
expression in lymphoma lymph nodes compared to
reactive nodes. The role of CCL3 in nHL has not been
described yet. Matsuhashi et al. presented a case re-
port of a patient with diffuse B-cell lymphoma, who
demonstrated strong osteolytic changes in bones at
the diagnosis of lymphoma [36]. Additionally in-
creased CCL3 expression was present, which could
explain massive osteolysis. In our study, lymphoma
lymph nodes were characterized by higher CCL3 ex-
pression compared to the reactive ones. In the afore-
mentioned work of Fujii et al., in all cases of DLBCL,
CCL3 expression was detected and increased in lym-
phomas with central nervous system involvement [22].
The CCL4 chemokine, which binds to CCR5 re-
ceptor, is related particularly to T lymphocytes. This
chemokine is involved in antigen-dependent B-cell
activation [36]. In our study, we did not notice differ-
ences in CCL4 expression between lymphoma and
reactive lymph nodes. It is known that CCL4 attracts
CD4+/CDRO+ T-cells [36] and activated B-cells in
mice show chemotactic activity on regulatory T lym-
phocytes through CCL4 [37, 38]. Recent work by Ek
et al. concerning CCL4 expression in MCL showed
CCL4 expression in lymphoma tissues as well as in
MCL cell lines [39]. In the study performed by Fujii,
in DLBCL expression of CCL4 was observed and the
level was particularly increased in nodal localization
of DLBCL [22]. Little is known about CCL4’s role in
lymphomas. Normal B-cells, after receptor rearrange-
ment, can secrete CCL4 chemokine. It is probable
that a high expression of CCL4, which is involved in
T-cell regulation, can influence the growth and sur-
vival of cancer cells in nHL.
CCL5, acting through CCR1, CCR3 and CCR5
receptors, is chemotactic for monocytes, T lympho-
cytes, eosinophils and mastocytes [40]. In T-cell pop-
ulation, CCL5 generally influences memory cells with
Th1 phenotype. CCL5 secreted by CD8+ lymphocytes,
thrombocytes, epithelial cells and fibroblasts, and re-
cruits leukocytes to the site of inflammation. Its ex-
pression has been shown in some neoplasms:
Hodgkin’s lymphoma (either CD20 cells or RSC),
breast cancer [41], prostate cancer [42] and melano-
ma [43], in which expression level was correlated with
decreased anti-neoplastic response and cancer pro-
gression. In our study, we observed high CCL5 ex-
pression in the majority of examined lymph nodes,
without significant differences between lymphoma
subgroups. In the study by Ek et al. on lymphoma
tissues and MCL cell lines, high CCL5 expression was
also observed [39].
Our results suggest that high expression of CCL5
(chemokine regulating T cells and follicular dendrit-
ic cells) in nHL can promote tumor growth. We also
found a positive correlation between CCL5 expres-
sion and proliferation index Ki-67 in lymphomas.
Murooka et al. found a new role for CCL5 as an im-
portant regulator of T-cell activity through apoptosis
induction [44]. At high concentration, CCL5 activates
mitochondrial/apoptosome pathway, induces apopto-
sis and causes T lymphocytes depletion, determining
immunologic response. Buri et al. noticed higher ex-
pression of CCR3 and CCR5 receptors for CCL5 on
B cells isolated from lymph nodes infiltrated by
Hodgkin’s lymphoma [9]. Interestingly, in the case of
B lymphocytes isolated from reactive and nHL lymph
nodes, a similar situation did not occur. Recently, it
has been shown that CCL5 as a ligand for CCR5 is
possibly involved in regulation of HL and RSC growth
and the formation of a microenvironment typical for
Hodgkin’s lymphoma [45].
The studies of inflammation and cancer have al-
ways run in parallel. Virchow in 1863 observed the
presence of lymphocytes in tumor tissue [46]. Inflam-
mation sustains the proliferation of cancer cells by stro-
mal cells activation and chemokines secretion. Some
chemokines, such as CXCL12 and CXCL13, have prov-
en roles in the pathogenesis of lymphoma [47, 48].
In our study, we observed different chemokine
gene expressions in lymphoma lymph nodes compared
to reactive lymph nodes. Lymphomas were charac-
terized by higher CCL2 and CCL3 expression, and
lower CXCL8 and CXCL10 expression than in reac-
tive lymph nodes. The expressions of CCL2 and
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CXCL10 seem to be important in cases of nHL, as they
have been shown to have value in predicting patients’
survival. Growing understanding of the mechanisms
that regulate cancer cell migration and proliferation
will help in introducing target therapy, which will re-
place or supplement standard chemotherapy.
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